News

Axogen, Inc. to report 2025 first quarter financial results on May 8, 2025

ALACHUA and TAMPA, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and…

8 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people…

8 months ago

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…

8 months ago

SpyGlass Pharma Presents 18-Month Data Demonstrating Compelling Visual Acuity Results with Their IOL-mounted Innovative Drug Delivery Platform

All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA)Significant IOP reduction at 18 months was also demonstrated…

8 months ago

NephroDI Therapeutics’ Founder and CMO Jeff M. Sands, M.D. Receives the 2025 Robert W. Berliner Award for Excellence in Renal Physiology

April 25, 2025, Seattle, WA – NephroDI Therapeutics (NephroDI), a pharmaceutical company focusing on kidney disorders, announces that its Founder…

8 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences

PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will…

8 months ago

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak®…

8 months ago

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the…

8 months ago

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and…

8 months ago

Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET

CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused…

8 months ago